Scholarlink

<p>With the growing prevalence of cognitive decline in ageing populations, accessible and scalable screening tools are essential for early intervention. This study investigated the potential of automated speech analysis as a proxy for cognitive assessment in 1003 older adults. Employing machine learning regression models, we demonstrated that linguistic and acoustic features extracted from spontaneous speech quadrupled performance compared to models using demographic information alone, when predicting cognitive domain scores. We then trained a binary classifier to identify individuals performing below normative thresholds (ROC-AUC up to 0.81), illustrating possible applications such as large-scale screening for cognitive impairment and improved participant selection for clinical trials. Finally, we evaluated our approach on an independent clinical dataset of Alzheimer’s disease (AD) patients and controls, demonstrating its generalizability. These findings highlight the clinical feasibility of speech analysis as a low-cost, non-intrusive digital biomarker for cognitive monitoring and screening.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Towards a speech-based digital biomarker for cognitive impairment: speech as a proxy for cognitive assessment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月31日

查看全文
  • Jonathan Heitz,
  • Ines M. Engler,
  • Nicolas Langer

摘要

With the growing prevalence of cognitive decline in ageing populations, accessible and scalable screening tools are essential for early intervention. This study investigated the potential of automated speech analysis as a proxy for cognitive assessment in 1003 older adults. Employing machine learning regression models, we demonstrated that linguistic and acoustic features extracted from spontaneous speech quadrupled performance compared to models using demographic information alone, when predicting cognitive domain scores. We then trained a binary classifier to identify individuals performing below normative thresholds (ROC-AUC up to 0.81), illustrating possible applications such as large-scale screening for cognitive impairment and improved participant selection for clinical trials. Finally, we evaluated our approach on an independent clinical dataset of Alzheimer’s disease (AD) patients and controls, demonstrating its generalizability. These findings highlight the clinical feasibility of speech analysis as a low-cost, non-intrusive digital biomarker for cognitive monitoring and screening.